Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04746924
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-31
First Post:
2021-02-05
Brief Title:
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Sponsor:
BeiGene
Organization:
BeiGene
Study Overview
Official Title:
A Phase 3 Randomized Double-Blind Study of Ociperlimab an Anti-TIGIT Antibody in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated PD-L1-Selected and Locally Advanced Unresectable or Metastatic Non-Small Cell Lung Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of ociperlimab tislelizumab compared with that of pembrolizumab in adults with PD-L1 high locally advancedrecurrent or untreated metastatic NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-004985-21 | EUDRACT_NUMBER | ChinaDrugTrials | None |
| BGB-A317-A1217-302 | OTHER | None | None |
| CTR20211476CTR20211464 | OTHER | None | None |